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ABSTRACT
“Vaults” are ubiquitously expressed endogenous ribonucleoprotein nanoparticles 
with potential utility for targeted drug delivery.  Here we show that recombinant 
human vault nanoparticles are readily engulfed by certain key human peripheral 
blood mononuclear cells (PBMC), predominately dendritic cells, 
monocytes/macrophages, and activated T cells. As these cell types are the primary 
targets for human immunodeficiency virus type 1 (HIV-1) infection, we examined 
the utility of recombinant human vaults for targeted delivery of antiretroviral drugs. 
We chemically modified three different antiretroviral drugs, zidovudine, tenofovir, 
and elvitegravir, for direct conjugation to vaults. Tested in infection assays, drug-
conjugated vaults inhibited HIV-1 infection of PBMC with equivalent activity to free 
drugs, indicating vault delivery and drug release in the cytoplasm of HIV-1-
susceptible cells. The ability to deliver functional drugs via vault nanoparticle 
conjugates suggests their potential utility for targeted drug delivery against HIV-1. 
KEYWORDS: Nanoparticle; drug conjugation; HIV-1; antiretroviral therapy; targeted
drug delivery
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INTRODUCTION
Targeted drug delivery can reduce drug toxicity while also increasing efficacy, and
has been successfully utilized in cancer chemotherapy and immunotherapeutics.1 
Delivering drugs specifically to sites and/or cells involved in disease reduces 
systemic and increases local exposure, thereby achieving more specific treatment. 
The use of nanotechnology for targeted drug delivery for anti-HIV microbicide 
development has been a promising focus because of the potential for these systems
to aid in distribution, retention, and specific delivery of drugs at the sites of 
infection.
Despite highly effective antiretroviral therapy to treat HIV-1 infection, there is still 
no effective vaccine or cure. With over 38,000 new HIV infections in 20172, 
prevention strategies are key to HIV eradication goals. Pre-exposure prophylaxis 
(PrEP), which is the use of antiretroviral drugs by HIV-negative persons to prevent 
HIV infection, is a highly effective prevention method; however, its efficacy is 
dependent upon medication adherence and tissue penetration.3-5 Additionally, since 
PrEP uses systemically administered medications, its use can have both side effects 
and long-term toxicities. Currently tenofovir disoproxil fumarate/emtricitabine fixed 
dose combination is the only drug approved for oral PrEP use, and long-term risks 
include renal toxicity and decreased bone mineral density.6-9 Thus, a major focus in 
HIV prevention research is methods usingAttempts to harness  such a 
strategytargeted drug delivery strategies to improve prevention of  for prevention 
of Human Immunodeficiency Virus-1 (HIV-1)HIV infection have while reducing 
potential toxicities. 
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Mucosal HIV-1 transmission accounts for the majority of transmission events. HIV-
1 primarily infects activated CD4+ T lymphocytes, the majority of which reside in 
the gastrointestinal mucosa10. Orally administered antiretroviral drugs have varying 
penetrations to rectal and vaginal mucosal tissues11. Thus, targeting therapy toward
the CD4+ T cells in these vulnerable tissues could lead to better efficacy with less 
drug. The most widely studied drug delivery system for HIV prevention has been 
included topical microbicides to deliver antiretroviral drugs. Numerous formulations 
and delivery systems have been developed as potential rectal and/or vaginal 
microbicides, yet none has progressed past early clinical testing. Common 
limitations have included insufficient bioavailability in the tissue, lack of efficacy, or 
poor tolerability and compliance by the user.12 Previous research has included 
studies of particular drugs as well as carrier formulations. Tenofovir was this first 
effective topical prevention antiretroviral drug,13 and the majority of microbicide 
trials have focused on tenofovir-based microbicides. Delivery systems have included
gels, creams, foams, capsules, enemas, and intravaginal rings. In order to reduce 
mucosal irritation, which can increase HIV infection risk, many studies have 
examined the inclusion of varying polymers and/or surfactants in carrier gels. While 
many formulations have shown promising safety and acceptability14-16, none have 
moved to clinical efficacy studies. 
14Improved delivery of antiretroviral drugs directly to the vulnerable cells 
mediating transmission of HIV-1 infection could may help overcome these 
limitations through enhanced bioavailability and therefore better efficacy with less 
drug. Nanoparticle delivery systems for antiretrovial drugs have included 
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dendrimers with inherent antiviral activity,17-18 polymer-based nanoparticles such as 
poly(lactic-co-glycolic acid),19-24 and lipid-based nanoparticles or liposomes.25-27 
Benefits of nanoparticle systems include the ability to traverse mucus layers due to 
small size which increases distribution and retention,23 and increased intracellular 
pharmacokinetics of the drug-loaded particles.28-29 For example, dapivirine-loaded 
poly(-caprolactone) nanoparticles, created using a solvent displacement method, 
are readily internalized by relevant HIV target cells and show at least similar 
efficacy as free drug in in vitro infection studies19 and surface engineering can 
ensure efficient penetration and retention in ex vivo mucosal studies20. The 
potential to improve targeted nanodelivery systems and delivery vehicles for HIV 
prevention is of continued clinical interest. 
Vault nanoparticles are highly conserved ribonucleoprotein particles that are 
expressed in most eukaryotic cells,30-31 yet their precise biological function remains 
unclear. Human vaults are barrel-shaped particles with outer shells comprised of 78 
copies of the major vault protein (MVP), which align non-covalently C- to N-terminus
to provide the overall vault structure.32-33 Naturally occurring vaults contain two 
additional proteins, vault poly(ADPribose) polymerase (VPARP) and telomerase-
associated protein 1 (TEP1), in addition to several copies of small untranslated vault
associated RNAs.34-36 Cellular expression of MVP alone is sufficient to form 
recombinant vault structures that can be loaded with certain molecules in vitro.37-39 
Recombinant vaults have been engineered for the purposes of vaccination,40-41 
enzyme delivery,42-43 targeting of cell surface receptors44, and local delivery of an 
immunotherapeutic for lung cancer.38 While it is known that vaults can be engulfed 
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by certain cells,45 the precise cell types that naturally take up vaults have not been 
fully defined.  
While protein packaging into recombinant vaults has been achieved through 
fusion with an interaction domain from VPARP that binds to a site on MVP within the 
interior of vaults,46 it is more challenging to achieve packaging of small molecule 
drugs. Although highly hydrophobic molecules have been loaded into recombinant 
vaults engineered to have internal hydrophobic domains,37 size, polarity, and 
solubility generally limit loading of vaults with drugs. Due to these limitations, we 
sought to examine the feasibility of using vault nanoparticles as a drug-targeting 
vehicle via drug conjugation rather than encapsulation. 
The majority of prior studies using nanodelivery for antiretroviral drugs have 
focused on the drug tenofovir (TFV),21, 24-25, 47-48 a nucleoside reverse transcriptase 
inhibitor, as it is the most widely studied drug for HIV prevention. TFV is widely used
for treatment49 and prevention50 of HIV-1 infection, but can also have significant 
adverse effects such as nephrotoxicity; thus, targeted delivery is of significant 
interest. The remainder of studies have focused on drugs from other classes 
generally selected based on hydrophobicity or other properties relevant for drug 
encapsulation. These drugs included protease inhibitors (indivavir51, saquinavir24, 28),
hydrophobic non-nucleoside reverse transcriptase inhibitors (efavirenz23-24, 
dapivirine19-20), and other drugs from the nucleoside reverse transcriptase inhibitors 
including zidovudine (AZT). AZT was the first FDA-approved drug to treat HIV-1, and
while highly effective is now less utilized due to systemic toxicities such as 
macrocytic anemia, granulocytopenia, myopathy, or mitochondrial toxicity.52-53 Its 
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hydrophilic nature have made it an attractive drug for initial feasibility studies of 
nanoparticle encapsulation,54-57 including one study with using non-covalent coating 
of nanoparticles.58  More recently, a few studies have examined the use of the 
newest class of antiretroviral drugs, integrase strand transfer inhibitors, including 
elvitegravir (EVG)21 and bictegravir22. EVG is a well tolerated drug, but undergoes 
rapid hepatic metabolism, requiring co-administration with an additional drug to 
inhibit its metabolism which can limit its clinical utility. All of these studies have 
focused on polymer or lipid nanoparticles, and employed methods such as oil in 
water emulsification or solvent displacement for nanoparticle encapsulation. Only 
prior studies using dendrimers utilized chemical conjugation for drug-loading18  . 
In this study, we find that the natural targets of vault uptake are cells that are 
highly relevant to the pathogenesis of HIV-1 infection and transmission, and that 
conjugation of antiretroviral drugs to human recombinant vault nanoparticles can 
achieve targeted drug delivery to these cells to inhibit HIV-1 infection. 
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RESULTS AND DISCUSSION
Vaults are efficiently internalized by antigen-presenting cells and 
activated T cells within human peripheral blood mononuclear cells. We 
examined the ability of different peripheral blood mononuclear cell (PBMC) lineages 
to engulf vaults by using fluorescence-labeled recombinant human vaults. Human 
PBMC readily took up recombinant vaults, with maximal uptake achieved by 20 
minutes (Figure 1A). To distinguish between cell surface binding versus 
internalization we compared uptake at 4C versus 37C in the presence or absence 
of trypan blue, an extracellular fluorescence quencher. With trypan blue, cellular 
fluorescence upon exposure to fluorescent vaults was abolished at 4C but not 37C,
suggesting that vaults are fully internalized by PBMC (Figure 1B).
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Figure 1. Vault internalization by human 
PBMC. (A) Fluorescence-labeled vaults were 
incubated with human PBMC for the indicated 
times, and then cell association (as indicated 
by cell fluorescence) was quantified via flow 
cytometry. Maximal cell fluorescence was 
achieved by 20 minutes. Data shown are mean
 standard deviation of 3 independent 
experiments. (B) To assess whether cell 
association occurs via surface binding versus 
internalization, PBMC were incubated with 
fluorescence-labeled vaults at 37C and 4C in 
the presence and absence of the extracellular 
fluorescence quencher trypan blue.  At 37C 
trypan blue did not significantly quench 
fluorescence, suggesting vault internalization, 
whereas at 4C (inhibiting internalization) 
trypan blue decreased fluorescence. Data 
shown as mean  standard deviation of 4 
independent experiments. 
The cell types within PBMC mediating vault internalization were further 
characterized using flow cytometry. The majority (77%) of cells taking up vaults 
were innate immune antigen presenting cells (APCs), specifically dendritic cells 
(CD3-CD19-CD11c+HLA-DR+) and monocytes/macrophages (CD3-CD19-CD14+HLA-
DR+CD11c-). A subset of B cells (CD27-IgD+ naïve B cells), which can also function as
APCs, also readily internalized vaults. Among T cells, primarily activated (CD38+) T 
cells were observed to internalize vaults, and nearly all (>90%) activated CD4+ T 
cells internalized vaults (Figure 2). 
Figure 2. Definition of PBMC subsets that internalize recombinant 
vaults. Human PBMC were incubated with fluorescence-labeled 
recombinant vaults and then stained with fluorescence-conjugated 
antibodies to identify specific cellular subsets using flow cytometry. 
Approximately 23% of all PBMC internalized vaults, as shown in the top left 
panel. Of these, approximately 16% were B cells (CD19+), 2% were T cells 
(CD3+) and 82% were not B or T cells. This latter subset was comprised 
primarily (77%) of dendritic cells (CD11c+HLA-DR+, bottom left). Among B 
cells that internalized vaults, the majority (74%) were naïve B cells (CD27-
IgD+, top right). Among T cells that internalized vaults, the majority (65%) 
were activated CD4+ T cells (bottom right). 
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As APCs and activated T cells are both capable of endocytosis and phagocytosis, 
these results suggested that either process could be a mechanism by which 
exogenous vaults are selectively taken up into these cells, consistent with prior 
work showing internalization and co-localization of vaults in the lysosome in the 
endocytic THP-1 human monocytic cell line.45 Binding saturation experiments using 
fluorescent vaults were inconclusive due to requirement for high vault 
concentrations (data not shown), and it was thus unclear whether vault uptake by 
these specific cells types is receptor mediated or nonspecific endocytosis or 
phagocytosis.  
Selection of antiretroviral drugs for direct conjugation to recombinant 
vault nanoparticles. The subsets of PBMC to which vaults naturally target are also
the key target cells for HIV-1 infection. As such, we tested the utility of using 
recombinant vaults for antiretroviral drug delivery. While vaults have been 
engineered to package highly hydrophobic molecules,37 available antiretroviral 
drugs against HIV-1 were not sufficiently hydrophobic to employ this method. 
Alternatively, we selected drugs that were amenable to direct conjugation to the 
vault, based on having reactive groups that would be either easily modifiable or 
directly available for protein conjugation using high-efficiency coupling methods. 
These included FDA-approved drugs from two clinically relevant antiretroviral drug 
classes, the nucleoside reverse transcriptase inhibitors and integrase strand 
transfer inhibitors. Specifically, the drugs chosen were zidovudine (AZT), tenofovir 
(TFV), and elvitegravir (EVG).  We chose to use ester-based conjugation strategies 
for each drug in order to provide a hydrolytically or enzymatically cleavable linkage 
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allowing slow, sustained release of the active drug only following cellular uptake. 
Additionally, this strategy also provided a direct route to modify the limited 
functional handles available on the selected drugs. The advantage of the direct 
conjugation strategiescovalent attachment of each drug to the vault nanoparticles 
versus the noncovalent encapsulation typically used in antiretroviral nanoparticle 
formulation is the potential to better regulate release kinetics and improve the 
precision of drug delivery. 
AZT was the first FDA-approved drug to treat HIV-1, and while highly effective is 
now less utilized due to systemic toxicities such as macrocytic anemia, 
granulocytopenia, myopathy, or mitochondrial toxicity.49-50 TFV is widely used for 
treatment51 and prevention52 of HIV-1 infection, but can also have significant 
adverse effects such as nephrotoxicity. EVG is well tolerated, but undergoes rapid 
hepatic metabolism, requiring co-administration with an additional drug to inhibit its
metabolism. 
Modification and conjugation of zidovudine to recombinant human vault 
nanoparticles. AZT was suitable for vault conjugation due to the presence of a 
single hydroxyl group at the 5’ position of the nucleoside, facilitating modifications 
without unwanted side products. We first added a succinate group through an ester 
linkage by reacting the 5’ hydroxyl group to succinic anhydride59 (Scheme 1). This 
linkage provided relative stability while allowing susceptibility to hydrolysis under 
acidic conditions or by esterases or nucleases, conditions present in the endosome 
and cytoplasm of cells,60-61 to regenerate the 5’ hydroxyl group in the active form of 
AZT. This modified drug molecule was then utilized for conjugation to the 3432 free 
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amine groups on vaults (43 lysine amine groups and an unmodified N-terminal 
amine per MVP, and 78 MVPs per vault).39 The carboxyl end of the functionalized 
AZT succinate was converted to an N-hydroxysuccinimide ester (AZT-NHS) using 
N,N’-dicyclohexylcarbodiimide (DCC) and N-hydroxysuccinimide (NHS)59 (Scheme 
1). 
Scheme 1. Synthesis of AZT-NHS. 
Scheme 2. Conjugation of AZT-NHS to recombinant vaults. 
This NHS ester was then conjugated to vaults through amide linkages to free amino 
groups on lysine (ε-amino) or N-termini (Scheme 2) using 3.28 molar equivalents of
AZT-NHS with respect to vault amines, resulting in an average of 1296 ± 3 AZT 
molecules per vault (37.8% derivatization of the 3432 vault amines) (Table 1). This 
efficiency exceeded a prior estimate that 9-16% of these vault amines are available 
for reactivity by NHS coupling.39 High performance liquid chromatography (HPLC) 
studies showed that the ester linkage between the AZT-vault was stable in 
Dulbecco's phosphate-buffered saline (DPBS) over 24 hours at ambient temperature
(data not shown). 
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Table 1. Efficiency of antiretroviral drug conjugation to vaults
Drug Equivalents/ # Drugs/Vault %
Modification and conjugation of tenofovir to recombinant human vault 
nanoparticles. Due to limited oral bioavailability, tenofovir is administered as a 
prodrug either tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide 
fumarate (TAF).62 Initial attempts were made to conjugate cleavable linkers to the 
exocyclic amine of TDF or TAF, but were unsuccessful due to the limited options of 
cleavable linkers that could be added to this amine. To circumvent this problem, we 
designed a novel tenofovir prodrug containing an oxycarbonyloxymethyl linker, 
similar to the linker found on TDF (Scheme 3). In place of the inert terminal 
isopropyl groups on TDF we used norbornene, providing a stable and orthogonal 
functional handle for conjugation of the prodrug to vaults. This was accomplished by
alkylative esterification of TFV using norbornene methyl(chloromethyl) carbonate to 
yield tenofovir-di-methylcarbonatemethlynorbornene (TFV-Nor) (Scheme 3) to 
create a prodrug that can undergo esterase hydrolysis in a manner similar to TDF. 
Scheme 3. Synthesis of TFV-Nor. 
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A methyltetrazine-PEG4-NHS ester linker was used to conjugate TFV-Nor to vaults, 
requiring a two-part reaction. First, the linker was attached to vault proteins by 
reacting the NHS ester of the linker with free amines of the vault. This yielded vaults
that were heavily decorated with methyltetrazine for selective reactivity with the 
norbornene of TFV-Nor through an irreversible inverse-electron-demand Diels-Alder 
reaction63-64 (Scheme 4). Vault conjugation was then performed using 5 molar 
equivalents of TFV-Nor with respect to vault amines, resulting in an average of 640 
± 4 TFV molecules per vault (18.8% derivatization of vault amines) (Table 1). 
Scheme 4. Conjugation of TFV-Nor to vaults. 
This conjugation efficiency was lower than AZT for two potential reasons. First, TFV-
Nor is significantly more hydrophobic than AZT-NHS, which likely led to increased 
aggregation of vault proteins when higher conjugation efficiencies were achieved. 
Second, having two tetrazine-reactive norbornene groups per molecule of TFV may 
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have cross-linked vaults, leading to loss of some vault particles. Despite these 
potential challenges, our TFV conjugation strategy still resulted in reasonable 
conjugation efficiency.
Modification and conjugation of elvitegravir to recombinant human vault 
nanoparticles. In addition to the two previous reverse transcriptase inhibitor 
drugs, we selected the integrase strand transfer inhibitor EVG, which contains a 
readily modifiable primary hydroxyl group amenable to an amine-reactive 
conjugation strategy analogous to AZT-NHS. However, the presence of a carboxylic 
acid on EVG precluded modification with an activated ester. Alternatively, EVG was 
reacted with N,N’-disuccinimidyl carbonate to create the N-hydroxysuccinimidyl 
carbonate of elvitegravir (EVG-NHS, Scheme 5). 
Scheme 5. Synthesis of EVG-NHS. 
Scheme 6. Conjugation of EVG-NHS to vaults. 
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Vault conjugation through carbamate linkages was then performed using 0.3 molar 
equivalent of EVG-NHS with respect to vault amines (Scheme 6), resulting in 67 ± 
5 EVG molecules per vault (1.9% derivatization of vault amines, Table 1). Being a 
more hydrophobic drug compared to AZT and TFV, EVG demonstrated the lowest 
conjugation efficiency as expected. Titration experiments showed that as the drug 
to amine ratio increased, overall vault recovery decreased, suggesting that 
increased hydrophobicity imparted by EVG conjugation to the vaults caused them to
precipitate. This phenomenon has similarly been reported for antibody-drug 
conjugates.65-68 Nonetheless, our drug-protein ratio greatly exceeded that of current 
antibody-drug conjugates,69 which are considered adequate for most targeted 
therapies. 
Antiretroviral drug-conjugated vaults effectively inhibit HIV-1 infection in 
human PBMC. To evaluate the function of our drug-conjugated vaults, we 
compared equivalent amounts of the drug conjugated to vaults versus free drug for 
the inhibition of in vitro HIV-1 infection of human PBMC. All drug-vault conjugates 
were similarly effective compared to free drug (Figure 3), indicating that vaults 
taken up intracellularly released the active form of drug for access to the 
cytoplasm. These results were not due to residual free drug in our vault conjugates, 
as multiple purification steps were performed and none was detectable by HPLC 
analyses (data not shown). 
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Figure 3. Vault-conjugated antiretroviral drugs inhibit HIV-1 infection in 
human PBMC. Equivalent concentrations of vault-conjugated drug or free drug 
were added to PBMC prior to infection with HIV-1 for 2 hours. Infection was 
quantified by intracellular p24 staining and normalized to no drug condition. Data 
shown as mean  standard deviation for 3 independent experiments. 
While the targeted drug-vault conjugates might have been predicted to have 
higher potency compared to free drug, this finding may be related to the assay, 
where direct exposure of PBMC to free drug in vitro would minimize any 
comparative advantage of vault targeting. Drug-targeting via vault conjugation 
could be advantageous in an in vivo setting where the key cells for HIV-1 infection 
are found in lower concentrations within tissues. Notably, the precise mechanism of 
drug release for these conjugates remains unknown; however, we expect that drug 
release is facilitated by either enzymatically or pH induced hydrolysis, or some 
combination thereof. Additionally, it has been demonstrated in the context of other 
protein-drug conjugates such as in antibody-drug conjugates that release of the 
original drug is not always required for full drug activity,70   so it is possible that the 
antiretrovirals are active as conjugates or peptide adducts. 
Additionally, at least one prior study showed that improved activity was only seen 
with specific drug combination deliveries, but not with single drugs.29 Our study 
focused on single drug formulations since in the context of HIV prevention, which is 
the most likely immediate clinical utility of such a targeted delivery method, 
combination antiretroviral therapy is not always necessary. Future studies certainly 
should include combining varying drug-vault conjugates together for the purpose of 
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improved prevention efficacy and/or multi-drug therapy for HIV treatment. Given 
that vaults are uniform nanoparticles with well-defined structure and functional 
groups amenable to covalent modification, they offer an ideal platform for precise 
drug delivery that can be widely adapted as nanocarriers for a variety of small 
molecule drugs. Vault nanoparticles can also be engineered to have antibody-
specific targeting,44 and one could potentially engineer CD4-targeted vaults to 
further improve targeting to HIV-susceptibile cells. CD4 targeting strategies has 
been used to improve nanodelivery of indinavir for HIV infection.51  
70Overall, our data have shown that functional drug can be effectively delivered via 
conjugation to recombinant human vault nanoparticles, which are naturally self-
targeted to the key cells involved in HIV-1 infection, potentially improving efficacy 
and minimizing systemic toxicity.  
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CONCLUSIONS
This study identified specific subsets of immune cells that readily take up human 
vault nanoparticles, predominantly antigen presenting cells (dendritic cells, 
monocytes/macrophages) and activated T cells. Because these are the key cell 
types infected by HIV-1, this suggests that vault targeting could be harnessed for 
antiretroviral drug delivery for HIV-1 prevention or treatment strategies to maximize
efficacy while minimizing systemic toxicity. As proof of concept, three anti-HIV-1 
drugs were directly conjugated to recombinant human vault nanoparticles. These 
vault-conjugated drugs retained antiviral activity against HIV-1 infection of PBMC, 
indicating intracellular access and release of active drug. This delivery system could
facilitate targeted drug delivery for HIV-1 prevention (e.g. microbicides) or 
enhanced treatment strategies.
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EXPERIMENTAL PROCEDURES (MATERIALS AND METHODS)
Recombinant human vault preparation.  Recombinant human vault particles 
were purified from baculovirus infected Sf9 insect cell pellets. Briefly, baculovirus 
infected Sf9 cells were lysed on ice in buffer A [50 mM Tris-HCl (pH 7.4), 75 mM 
NaCl, and 0.5 mM MgCl2] with 1% Triton X-100, 1 mM DTT, 0.5 mM PMSF, and 
protease inhibitor cocktail (Sigma 8849). Lysates were dounced on ice and 
centrifuged at 20,000g for 20 minutes. The supernatant fraction was then 
centrifuged at 100,000g for 1 hour to pellet the vaults. Following resuspension, the 
vault particles were purified by sucrose gradient as described previously.71
Fluorescent vault labeling and uptake.  Purified recombinant human vaults 
were fluorescently labeled using DyLight-488 amine-reactive dye according to 
manufacturer’s recommendations (Thermo Scientific). For uptake studies, human 
peripheral blood mononuclear cells (PBMC) were obtained from de-identified donors 
through the UCLA Center for AIDS Research Virology Core. Fluorescent vaults at a 
concentration of 1 g/ml were incubated with 1x106 PBMC in RPMI/10% FBS for 
indicated times (5 min to 2 hours) at 37C then immediately fixed in 2% 
paraformaldehyde or placed on ice for flow cytometry staining. For the trypan blue 
experiments, 0.4 mg/ml trypan blue was added to the sample immediately prior to 
data acquisition on the flow cytometer. 
Flow cytometry.  PBMC were stained in PBS with 1% human AB serum for 30 
minutes on ice using fluorescent-conjugated antibodies as described in detail in 
Supporting Information. Cells were washed with cold PBS at 10X the staining 
volume then fixed using 1% paraformaldehyde. Data was acquired on a Becton 
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Dickinson LSRFortessa cytometer and analyzed using FlowJo v10 (FlowJo, LLC). Live 
cells were gated using Live/Dead Aqua (Life Technologies) and singlets gated with 
FSC-H and FSC-A parameters. Following this a large lymphocyte cell gate was 
created by forward and side scatter parameters. Vault+ gates were determined 
using “no vault” conditions as background, and all other staining gates based on 
isotype controls.  
Chemical materials. Triethylamine (TEA) and N-methyl-2-pyrrolidone (NMP) were 
dried with 3 Å molecular sieves and then distilled prior to use. Tetrahydrofuran 
(THF), acetonitrile (MeCN), and dichloromethane (DCM) were dried by purging with 
nitrogen and passage through activated alumina columns prior to use. Zidovudine 
and tenofovir were purchased from Combi-Blocks, elvitegravir from eNovation 
Chemicals, and the methyltetrazine-PEG4-NHS ester linker from Click Chemistry 
Tools. All other chemicals were used as purchased unless otherwise noted from 
Acros, Alfa Aesar, Sigma Aldrich, Chem-Impex, or Fisher Scientific. 
Analytical techniques. NMR spectra were obtained using either Bruker AV400 or 
Bruker AV500 spectrometer. ESI mass spectra were obtained using either a Waters 
Acquity LCT Premier XE equipped with an autosampler and direct injection port or 
an Agilent 6530 QTOF-ESI with a 1260 Infinity LC with autosampler. Analytical 
reverse phase high performance liquid chromatography (HPLC) was carried out on a
Agilent 1260 Infinity II HPLC system equipped with an autosampler and a UV 
detector using a Poroshell 120 2.7 µm C18 120 Å column (analytical: 2.7 µm, 4.6 × 
100 mm) with monitoring at λ = 220 and 280 nm and with a flow rate of 0.8 ml/min.
Preparatory reverse phase HPLC was carried out on a Shimadzu high performance 
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liquid chromatography system equipped with a UV detector using a Luna 5 µm C18 
100 Å column (preparatory: 5 µm, 250 × 21.2 mm) with monitoring at λ = 215 and 
254 nm and with a flow rate of 20 ml/min. 
Synthesis of AZT succinate. The synthesis of AZT succinate was accomplished by
modifying a preexisting procedure.59 Succinic anhydride (0.120 g, 1.19 mmol, 1.6 
eq) was added to a round bottom flask containing a stirring solution of AZT (0.200 
g, 0.75 mmol, 1.0 eq) in THF (10 mL). After succinic anhydride was fully dissolved, 
TEA (0.184 mL, 1.32 mmol, 1.8 eq) was slowly added to the flask. The reaction 
mixture was refluxed for 16 hours and was then concentrated under reduced 
pressure. Excess succinic anhydride was removed by dissolving the dried reaction 
content in DI water (20 mL) and ethyl acetate (EtOAc) (20 mL). The aqueous layer 
was basified to pH 7.0 using 3.0 M NaOH and succinic anhydride was extracted with 
3 X EtOAc (20 mL). The aqueous layer was then adjusted to pH 3.0 using 
concentrated HCl and the product was extracted using 3 X EtOAc (20 mL). The 
organic fractions were collected, dried with anhydrous sodium sulfate, and 
concentrated under reduced pressure. Final purification was accomplished using 
silica flash column chromatography, 20% methanol (MeOH)/EtOAc to yield a white 
solid (0.203 g, 73.7% yield). See Supporting Information Figure S1 for 1H NMR (400 
MHz, CDCl3, 25 °C): δ 10.64–10.53 (br s, 1H), 7.44 (d, J = 1.1 Hz, 1H), 5.91 (td, J = 
5.7, 1.4 Hz, 1H), 4.79 (dd, J = 12.7, 1.7 Hz, 1H), 4.34 (dt, J = 7.2, 4.0 Hz, 1H), 4.28 
(dd, J = 12.7, 3.8 Hz, 1H), 4.11 (td, J = 3.9, 1.7 Hz, 1H), 2.92-2.81 (m, 1H), 2.77-
2.57(m, 4H), 2.40 (ddd, J = 13.8, 6.7, 5.1 Hz, 1H), 1.87 (d, J = 1.1, 3H). See 
Supporting Information Figure S2 for 13C NMR (100 MHz, CDCl3, 25 °C): δ 177.9, 
172.8, 166.5, 149.5, 137.6, 109.8, 85.9, 83.0, 63.2, 60.3, 38.1, 29.0, 28.8, 12.5.  
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FTIR: ν = 3177, 3021, 2934, 2103, 1682, 1651, 1473, 1407, 1365, 1321, 1267, 
1156, 1096, 1064, 997, 957, 895, 829, 776 cm-1. HRMS: Calc. [M-1] = 366.1050 Da; 
Obs. [M-1] = 366.1108 Da.
Synthesis of AZT-NHS. AZT succinate (0.506 g, 1.37 mmol, 1.0 eq), NHS (0.153 g,
1.37 mmol, 1.0 eq), and dicyclohexylcarbodiimide (DCC) (0.270 g, 1.37 mmol, 1.0 
eq) were placed in a Schlenk flask and dissolved in THF (30 mL). The reaction was 
performed under nitrogen, cooled to 0 °C, and stirred for 2 hours. This led to a 
heterogeneous reaction mixture, which was concentrated under reduced pressure 
to yield a white solid. The product was purified using silica flash column 
chromatography, 0% EtOAc/hexanes to 100% EtOAc/hexanes. The sample was then 
crystallized 4 X, 40% DCM/hexanes to remove excess DCC. Preparative HPLC was 
performed to remove excess NHS to yield a white solid (0.416 g, 65.0% yield). See 
Supporting Information Figure S3 for 1H NMR (400 MHz, CDCl3, 25 °C): δ 9.22-9.09 
(br s, 1H), 7.24 (d, J = 1.1 Hz, 1H), 6.07 (t, J = 6.4 Hz, 1H), 4.44 (dd, J = 12.2, 4.3 Hz,
1H), 4.36 (dd, J = 12.2, 3.8 Hz, 1H), 4.24 (dt, J = 7.4, 5.7 Hz, 1H), 4.04 (dt, J = 5.5, 
4.1 Hz, 1H), 3.04-2.95 (m, 2H), 2.84 (s, 4H), 2.81 (t, J = 6.6 Hz), 2.53-2.35 (m, 2H), 
1.93 (d, J = 1.1 Hz, 3H). See Supporting Information Figure S4 for 13C NMR (100 
MHz, CDCl3, 25 °C): δ 170.7, 169.1, 167.9, 164.2, 150.1, 136.2, 111.4, 85.9, 81.8, 
63.6, 60.3, 37.5, 28.9, 26.4, 25.7, 12.6. FTIR: ν = 3190, 3021, 2970, 2106, 1813, 
1782, 1733, 1682, 1471, 1407, 1365, 1316, 1261, 1202, 1089, 1068, 1046, 995, 
959, 892, 849, 805 cm-1. HRMS: Calc. [M+1] = 465.1370 Da; Obs. [M+1] = 465.1429
Da. High-resolution mass spectrometry (HRMS) of final AZT-NHS product is shown in
Supporting Information Figure S11. 
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Synthesis of norbornene methyl (chloromethyl) carbonate. TEA (0.868 mL, 
6.20 mmol, 1.5 eq) was slowly added to a 0 °C solution of 5-norbornene-2-methanol
(0.50 mL, 4.14 mmol, 1.0 eq) in DCM (20 mL). After 5 minutes, chloromethyl 
chloroformate (0.40 mL, 4.55 mmol, 1.1 eq) was added dropwise and the reaction 
mixture was allowed to come to room temperature and stir for 2 hours. The reaction
was quenched with DI water (20 mL) and the product was extracted using 4 X DCM 
(20 mL). The organic fractions were combined, dried using anhydrous sodium 
sulfate, and concentrated under reduced pressure. The product was purified using 
silica flash column chromatography, 0% EtOAc/hexanes to 5% EtOAc/hexanes. 
Fractions were concentrated under reduced pressure to yield a light yellow oil which
was vacuum distilled to give a colorless oil (0.585 g, 65.3% yield). See Supporting 
Information Figure S5 for 1H NMR (400 MHz, CDCl3, 25 °C): δ 6.18 (dd, J = 5.7, 3.0 
Hz, 0.7H), 6.09 (t, J = 1.6 Hz, 0.6H), 5.96 (dd, J = 5.7, 2.9 Hz, 0.7H), 5.74 (s, 0.6H), 
5.73 (d, J = 0.6 Hz, 1.3H), 4.30 (dd, J = 10.6, 6.4 Hz, 0.3H), 4.13 (dd, J = 10.6, 9.3 
Hz, 0.3H), 4.00 (dd, J = 10.4, 6.7 Hz), 3.82 (dd, J = 10.4, 9.5 Hz, 0.7H), 2.95 – 2.88 
(br s, 0.7 H), 2.88 – 2.80 (br s, 1H), 2.77 – 2.72 (br s, 0.3H), 2.51 – 2.41 (m, 0.7H), 
1.88 (dd, J = 9.2, 3.8 Hz, 0.4H), 1.85 (dd, J = 9.2, 3.8 Hz, 0.4H), 1.83 - 1.75 (m, 
0.3H), 1.55 (s, 0.2H), 1.85 (dd, J = 9.2, 3.8 Hz, 0.3H), 1.48 (dd, J = 4.1, 2.0 Hz, 
0.4H), 1.39 (td, J = 3.3, 1.7 Hz, 0.1H), 1.37 (td, J =  1.62, 0.6 Hz, 0.2H), 1.34 -1.33 
(m, 0.1H), 1.32 – 1.31 (br s, 0.2H), 1.31 – 1.29 (m, 0.2H), 1.29 – 1.27 (br s, 0.5H), 
1.27 – 1.25 (br s, 0.3H),  1.19 (dd, J = 4.4, 3.5 Hz, 0.2H), 1.16 (dd, J = 4.4, 3.5 Hz, 
0.1H) 0.57 (ddd, J = 11.8, 4.4, 2.6 Hz, 0.7H). See Supporting Information Figure S6 
for 13C NMR (100 MHz, CDCl3, 25 °C): δ 153.6, 153.5, 138.1, 137.2, 136.2, 132.2, 
73.3, 72.7, 72.3, 72.3, 49.6, 45.1, 43.9, 43.6, 42.3, 41.7, 38.1, 37.8, 29.5, 28.9. 
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FTIR: ν = 3061, 2968, 2870, 1761, 1570, 1444, 1390, 1341, 1326, 1239, 1226, 
1153, 1110, 1025, 1012, 992, 978, 958, 928, 882, 858, 836, 825, 786, 713 cm-1.
Synthesis of TFV-Nor. Tenofovir (0.210 g, 0.73 mmol, 1.0 eq) and 
tetrabutylammonium bromide (TBAB) (0.235 g, 0.73 mmol, 1 eq) were added to a 
Schlenk flask and placed under reduced pressure at 50 °C for 16 hours to remove 
residual water. NMP (25 mL), TEA (0.41 ml, 2.92 mmol, 4 eq), and norbornene 
methyl (chloromethyl) carbonate (0.788 g, 3.63 mmol, 5 eq) were added to the 
reaction flask. The reaction was placed under nitrogen and heated to 50 °C for 2 
days. The reaction was cooled to room temperature and concentrated under 
reduced pressure. The resulting residue was dissolved in DI water (20 mL) and the 
product was extracted using 4 X EtOAc (20 mL). The organic layers were combined, 
dried using anhydrous sodium sulfate, and concentrated under reduced pressure. 
The product was then subjected to silica flash column chromatography, 0% 
MeOH/EtOAc to 5% MeOH/EtOAc. Fractions were concentrated under reduced 
pressure to yield a light yellow oil which was further purified using preparative HPLC
to give a white solid (0.264 g, 55.7% yield). See Supporting Information Figure S7 
for 1H NMR (400 MHz, CDCl3, 25 °C): δ 8.29 (s, 1H), 8.28 (s, 1H), 8.21 – 8.10 (br s, 
1H), 6.14 (dd, J = 5.6, 3.0 Hz, 1.4H), 6.08 – 6.01 (br s, 1.1H), 5.89 (dd, J = 5.4, 2.5 
Hz, 1.4H), 5.69 – 5.52 (m, 4H), 4.43 (dd, J = 14.4, 2.5 Hz, 1H), 4.28 – 4.11 (m, 1.6H),
4.09 – 3.88 (m, 4.1H), 3.81 – 3.65 (m, 2.4H), 2.89 – 2.83 (br s, 1.5H), 2.83 – 2.74 (br 
s, 1.9H), 2.69 –2.64 (br s, 0.5H), 2.45 – 2.32 (m, 1.5H), 1.80 (ddd, J = 12.0, 9.0, 3.4, 
Hz, 1.4H), 1.76 – 1.67 (m, 0.6H), 1.47 – 1.39 (m, 1.9H), 1.36 – 1.30 (m, 0.6H), 1.28 – 
1.19 (m, 5.6H), 1.12 (dt, J = 11.8, 3.9, Hz, 0.6H), 0.52 (m, 1.4H)m. See Supporting 
Information Figure S8 for 13C NMR (100 MHz, CDCl3, 25 °C): δ 153.78, 153.75, 
153.69, 153.66, 151.5, 149.1, 144.8, 144.6, 138.06, 137.2, 136.0, 131.9, 117.9, 
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117.3, 84.5, 76.3, 76.2, 73.2, 72.6, 63.7, 62.1, 49.5, 48.8, 45.0, 43.8, 43.5, 42.2, 
41.6, 38.0, 37.8, 29.4, 28.8, 16.3. FTIR: ν = 3061, 2970, 2872, 1760, 1693, 1515, 
1468, 1420, 1387, 1350, 1327, 1248, 1197, 1139, 1038, 1003, 947, 927, 897, 858, 
826, 786, 765, 720 cm-1. HRMS: Calc. [M+1] = 648.2435 Da; Obs. [M+1] = 
648.2083 Da. HRMS of final TFV-Nor product is shown in Supporting Information 
Figure S12.
Synthesis of EVG-NHS. To a previously oven dried 2-neck 25 ml round bottom 
flask under Argon was added N,N'-disuccinimidyl carbonate (0.143 g, 0.53 mmol, 5 
eq) and 4 ml dry MeCN. In a separate vial was dissolved EVG (0.050 g, 0.11 mmol, 1
eq) in 3 ml dry MeCN and TEA (0.047 ml, 0.33 mmol, 3 eq) while under Argon. This 
solution of EVG was briefly mixed and then added dropwise via syringe into the 
solution of N,N'-disuccinimidyl carbonate. The reaction was stirred at 22 °C for 5 
hours, then the solvent was completely removed under vacuum. The crude material
was purified using preparative HPLC followed by removal of solvent under vacuum 
to yield a yellow solid (30.93 mg, 46.9% yield). See Supporting Information Figure 
S9 for 1H NMR (500 MHz, CDCl3, 25 °C): δ 8.73 (s, 1H), 8.25 (s, 1H), 7.25 (dd, J = 
14.8, 1.4 Hz, 1H), 7.06 (t, J =7.1 Hz, 1H), 6.98 (t, J = 7.8 Hz, 1H), 6.94 (s, 1H), 4.89 
(d, J = 9.8 Hz, 1H), 4.73 (m, 2H), 4.10 (q, J = 12.9 Hz, 2H), 3.99 (s, 3H), 2.73 (s, 4H), 
2.42 (m, 1H), 1.25 (d, J = 6.3 Hz, 3H), 0.83 (d, J = 6.5 Hz, 3H). See Supporting 
Information Figure S10 for 13C NMR (126 MHz, CDCl3, 25 °C): δ 177.2, 168.2, 167.9, 
163.0, 157.5, 151.3, 143.5, 142.4, 129.42, 129.41, 129.38, 128.96, 128.90, 128.47, 
127.83, 127.71, 124.44, 124.40, 121.17, 121.03, 119.7, 109.3, 95.6, 70.0, 64.4, 
56.2, 30.8, 29.05, 29.03, 25.4, 19.8, 19.5. FTIR: ν = 2957, 2920, 1814, 1789, 1739, 
1613, 1456, 1374, 1305, 1257, 1195, 1152, 1095, 1047, 1012, 991, 923, 878, 810, 
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790, 753, 732 cm-1. HRMS: Calc. [M+1] = 589.1389 Da; Obs. [M+1] = 589.1391 Da. 
HRMS of final EVG-NHS product is shown in Supporting Information Figure S13.
Conjugation of AZT-NHS to vaults. 0.5 mg of lyophilized human MVP (hMVP) 
vaults were resuspended in 125 µl 1x DPBS.  1 µl of 200 µg/µl AZT-NHS stock 
solution in DMSO was added to 74 µl of 4 µg/µl hMVP vaults in 1 x DPBS. The 
reaction was incubated at room temperature for 2 hours. AZT conjugated vaults 
were purified from unconjugated AZT-NHS by gel exclusion chromatography using 
Bio-Gel® P polyacrylamide P-6 Columns. To further eliminate any potential 
contamination of the AZT conjugated vaults with free AZT-NHS, a stepwise sucrose 
gradient (sucrose fractions of 20%, 30%, 40%, 45%, 50% and 60%) was performed. 
The sucrose gradient was spun at 25K, 16 hours, 4 °C, ω2t=3.95E11 in a sw41 rotor.
Sucrose fractions (40% and 45%) containing AZT conjugated vaults were collected, 
diluted in 1 x DPBS and spun at 40K for 2 hours, 4 °C in a Ti 70.1 rotor. The resulting
AZT-vault pellet was washed with 6.5 ml of 1x DPBS and centrifuged at 40K for 1 h, 
4 °C in a Ti70.1 rotor. The wash step was repeated 2x to ensure the complete 
removal of any residual sucrose. Subsequently, the washed pellet was resuspended 
in 150 µl of 1x DPBS, filtered via 0.2 µm syringe filter and the protein concentration 
determined by BCA assay. The concentration of the vaults was found to be 0.81 g/
l.
Conjugation of TFV-Nor to vaults. 1 mg of lyophilized recombinant human 
vaults was added 1375 l DPBS and the lyophilized cake was dissolved by gentle 
shaking. NHS-TEG-tetrazine linker was then added (125 l of a 4 g/l stock solution
prepared in DMSO; 0.50 mg; 0.562 μmol; 2.25 eq./lysine). The reaction was then 
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mixed on a rocker table at 22 °C for 2 hours. The unreacted linker was then 
removed by centrifugal filtration using a pre-equilibrated 30 kDa MW cutoff filters. 
The contents were centriprepped 5 times and the products collected by inverse 
centrifugation. This material was diluted in 1407 l of DPBS in a new 1.5 ml tube 
and TFV-Nor was added (93 l of a 15 g/l stock solution prepared in DMSO; 1.40 
mg; 2.16 mol; 5 eq./lysine). Some drug precipitated, but the conjugation was 
continued on the rocker for 24 hours followed by purification by sucrose gradient as 
described above. The vaults eluted in the 40 and 45% fractions and were collected 
and their concentration measured via standard BCA Assay. The concentration of the
vaults was found to be 0.554 g/l.
Conjugation of EVG-NHS to vaults. 1 mg of lyophilized recombinant human 
vaults was added 950 l DPBS, then transferred to a 2 ml LoBind tube. Another 950 
l DPBS was used to wash the tube and also transferred to the 2 ml tube for a total 
volume of 1900 l. 23.5 l DMSO was then added to the 2 ml tube. Then, EVG-NHS 
was added (76.5 l of 1 g/l stock solution prepared in DMSO; 0.076 mg; 0.13 
μmol; 0.3 eq./lysine). The conjugation was gently mixed on a rocker table for 4 
hours at 22 °C followed by purification by sucrose gradient as described above. The 
conjugate eluted in the 40 and 45% fractions and was collected and its 
concentration determined to be 1.469 g/l via standard BCA Assay.
General procedure for quantification of drug-vault conjugates via HPLC. An
HPLC standard curve for each antiretroviral was generated by measuring the peak 
area (280 nm absorbance) after injecting, in triplicate, 1, 5, 10, 50, 100, 500, and 
1000 ng of each drug and plotting the corresponding peak areas against the 
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amount of drug injected. After generating these standard curves, the average 
number of drugs per vault was determined for each conjugate via basic hydrolysis 
of the labile linkages (either ester or carbamate) between drug molecules to release
the native drug. The area under the peak corresponding to the retention time of 
each drug was then used to determine the amount of drug injected, which was then
used to calculate the number of drugs attached to each vault. Additionally, a 
negative control consisting of the conjugate with no NaOH added was used to 
determine the amount of free drug before basic hydrolysis, and this amount was 
subtracted from the amount of calculated conjugated drug.
Preparative HPLC. AZT-NHS was purified using a mobile phase consisting of 10-
95% MeCN + 0.1% trifluoroacetic acid (TFA) in water beginning with 1 min isocratic 
at 10%, then up to 95% over 15 min in a linear gradient, followed by an isocratic 
hold at 95% MeCN + 0.1% TFA for 4 min (total time was 20 min; product eluted at 
13.5 min). TFV-Nor was purified using a mobile phase consisting of 40-95% MeCN + 
0.1% TFA in water beginning with 1 min isocratic at 40%, then up to 95% over 15 
min in a linear gradient, followed by an isocratic hold at 95% MeCN + 0.1% TFA for 
4 min (total time was 20 min; product eluted at 12.0 min). EVG-NHS was purified 
using a mobile phase consisting of 50-95% MeCN + 0.1% TFA in water beginning 
with 1 min isocratic at 50%, then up to 95% over 15 min in a linear gradient, 
followed by an isocratic hold at 95% MeCN + 0.1% TFA for 4 min (total time was 20 
min; product eluted at 15.8 min).
Analytical HPLC. Zidovudine was analyzed using a mobile phase consisting of 10-
100% MeCN + 0.1% TFA in water beginning with a 1 min isocratic at 10%, then up 
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to 100% over 10 min in a linear gradient, followed by an isocratic hold at 100% 
MeCN + 0.1% TFA for 4 min (total time was 15 min; product eluted at 5.9 min). 
Tenofovir was analyzed using a mobile phase consisting of 5-100% MeCN + 0.1% 
TFA in water beginning with 5 min isocratic at 5%, then up to 100% over 6 min in a 
linear gradient, followed by an isocratic hold at 100% MeCN + 0.1% TFA for 4 min 
(total time was 15 min; product eluted at 3.1 min). Elvitegravir was analyzed using 
a mobile phase consisting of 10-100% MeCN + 0.1% TFA in water beginning with a 
1 min isocratic at 10%, then up to 100% over 10 min in a linear gradient, followed 
by an isocratic hold at 100% MeCN + 0.1% TFA for 4 min (total time was 15 min; 
product eluted at 11.0 min).
HIV-1 stock preparation. The following reagent was obtained from the NIH AIDS 
Reagent Program, Division of AIDS, National Institute of Allergy and Infectious 
Diseases (NIAID), NIH: HIV-1BaL from Dr. Suzanne Gartner, Dr. Mikulas Popovic and 
Dr. Robert Gallo. Stocks of HIV-1BaL were prepared by infection using PBMC from 
multiple HIV-1-uninfected donors. Virus titer was determined by titration using Rev 
response element (RRE)-GFP reporter T1 cells. The same viral stock was used 
throughout the study. 
HIV-1 infection of PBMC and intracellular p24 staining. Activated PBMC were 
pre-incubated with indicated concentration of antiretroviral drug or drug-vault 
conjugate for two hours at 37C.  PBMC (1x105 cells) were infected in duplicate with 
0.5 multiplicity of infection (MOI) HIV-1BaL for two hours at 37C then washed three 
times with RPMI and plated in 48-well plates. Cultures were maintained in RPMI/10%
FBS for 5 days then cells were harvested for intracellular p24. Staining was 
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performed using Fix/PERM kit (R&D Systems) and KC57 (clone FH190-1-1)-PE 
conjugated antibody (Coulter) according to manufacturer’s instructions then fixed in
2% paraformaldehyde until flow cytometry acquisition. Data was acquired using a 
FACScan flow cytometer (Becton Dickinson) and analyzed using FlowJo v10 (FlowJo, 
LLC). Infection was quantified as percent of cells with p24 expression then 
normalized to 100% infection using the control infection (no drug) for each 
independent experiment. 
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ABBREVIATIONS 
HIV-1, Human Immunodeficiency Virus-1; MVP, major vault protein; VPARP, vault 
poly(ADPribose) polymerase; TEP1, telomerase-associated protein 1; PBMC, 
peripheral blood mononuclear cells; AZT, zidovudine; TFV, tenofovir; EVG, 
elvitegravir; TEA, triethylamine; DCC, N,N’-dicyclohexylcarbodiimide; NHS, N-
hydroxysuccinimide; HPLC, high performance liquid chromatography; DPBS, 
Dulbecco's phosphate-buffered saline; TDF, tenofovir disoproxil fumarate; TAF, 
tenofovir alafenamide fumarate; TFV-Nor, tenofovir-di-
methylcarbonatemethlynorbornene; DTT, Dithiothreitol; PMSF, phenylmethylsulfonyl
fluoride; NMP, N-methyl-2-pyrrolidone; THF, Tetrahydrofuran; MeCN, acetonitrile; 
DCM,  dichloromethane; EtOAc, ethyl acetate; MeOH, methanol; HRMS, high-
resolution mass spectrometry; TBAB, tetrabutylammonium bromide; hMVP, human 
major vault protein; TFA, trifluoroacetic acid.
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